Moleculin Biotech — Third Quarter 2026 Earnings Summary
Financial Performance:
- Revenue was $0 for the three and nine months ended September 30, 2026, compared to $0 in the same periods of 2025.
- Research and development expenses were $4.5 million for the three months ended September 30, 2026, up from $3.7 million in the prior-year period; for the nine months, expenses were $15.3 million compared to $10.8 million in 2025.
- General and administrative expenses were $2.1 million for the three months ended September 30, 2026, flat compared to $2.1 million in 2025; for the nine months, expenses were $6.7 million compared to $6.7 million in 2025.
- Net loss was $6.5 million for the three months ended September 30, 2026, a decrease from $25.4 million in the same period of 2025, primarily due to the absence of a $20.6 million non-cash loss on warrant liabilities recorded in the prior year.
- Net loss for the nine months ended September 30, 2026, was $27.0 million, compared to $49.1 million in 2025.
- Net loss per share (basic and diluted) was $9.59 for the three months ended September 30, 2026, compared to $340.43 in 2025; for the nine months, it was $71.38 compared to $1,179.03 in 2025.
- Cash and cash equivalents were $7.3 million as of September 30, 2026, down from $8.9 million as of December 31, 2025.
- Net cash used in operating activities was $21.7 million for the nine months ended September 30, 2026.
- Total liabilities were $6.2 million as of September 30, 2026, compared to $7.1 million as of December 31, 2025.
- Warrant liability decreased to $5,000 as of September 30, 2026, from $44,000 as of December 31, 2025.
Guidance and Future Outlook:
- Comprehensive Part A data from the MIRACLE trial is on track for the first quarter of 2027.
- Part B of the MIRACLE trial is planned to begin in the first half of 2027 following optimal dose selection.
- A physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer is planned for the first half of 2027.
- A third-line relapsed/refractory AML subject trial and a pediatric AML clinical study are planned for the first half of 2028.
- Recruitment for Part B is planned to be completed in the second half of 2028.
- Primary efficacy data for MIRACLE second-line subjects is expected in the second half of 2028.
- A rolling submission of a New Drug Application (NDA) for relapsed/refractory AML is planned for 2028-2029.
- The Company requires significant additional financing to conduct clinical trials and has no commitments for such funding.
Business Segments and Product Lines:
- The MIRACLE trial (Phase 2/3) evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) has completed treatment of all 90 patients in Part A.
- Annamycin's cardiac safety profile was supported by a peer-reviewed analysis of 90 patients across five clinical trials, showing no evidence of clinical or subclinical cardiotoxicity.
- New preclinical data presented at the AACR Conference suggests Annamycin may convert immunologically "cold" pancreatic tumors to "hot," supporting potential combination therapies.
- The WP1066 program continues to be supported through investigator-sponsored research, including a Phase 1B/2 trial for glioblastoma.
- The Company has a portfolio of antimetabolites, including WP1122, for potential treatment of pathogenic viruses and certain cancer indications.
Market and Competitive Landscape:
- The Company aims to address a meaningful treatment gap in relapsed or refractory AML with Annamycin.
- Annamycin is designed to avoid multidrug resistance mechanisms and lacks the cardiotoxicity common with conventional anthracyclines.
- The Company plans to release quantitative market research data soon to support the commercial opportunity for Annamycin.
Risks and Challenges:
- The Company has no commitments for the significant additional financing required to conduct clinical trials.
- Clinical trial results and timelines are subject to risks, uncertainties, and potential changes in FDA feedback.
- Forward-looking statements regarding efficacy, safety, and timelines involve known and unknown risks, including the possibility that expectations may prove materially different from results.
- The Company relies on expert reports regarding the absence of cardiotoxicity, which are subject to review of future data.
Management Commentary and Tone:
- Walter Klemp, Chairman and CEO, stated the Company is approaching a critical milestone and believes progress has positioned them to enter 2027 with meaningful momentum.
- Management highlighted the completion of Part A treatment as a significant execution achievement and expressed confidence in the totality of evidence generated to date.
- The tone emphasized a clear priority to execute on the data readout, make informed development decisions, and advance Annamycin toward critical milestones.
Other Key Points:
- Data from the MIRACLE trial was accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting.
- The Company reported a gain of $35,000 from the change in fair value of warrant liability for the three months ended September 30, 2026, compared to a loss of $20.6 million on the issuance of warrant liabilities in the prior year.
- The Company's lead program, Annamycin (naxtarubicin), is currently in development for relapsed or refractory AML and soft tissue sarcoma lung metastases.
- The MIRACLE trial is a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial.
- Company
- MOLECULIN BIOTECH INC
- Sector
- Healthcare
- Industry
- Biotechnology